JAMDA
Volume 8, Issue 3, Supplement 2 , Pages e51-e57 , March 2007

The Application of Evidence-Based Principles of Care in Older Persons (Issue 1): Management of Osteoporosis

  • Barbara J. Zarowitz, PharmD, FCCP, BCPS, CGP

      Affiliations

    • College of Allied Health Sciences, Wayne State University, Detroit, MI
    • Omnicare, Inc., Livonia, MI.
    • Corresponding Author InformationAddress correspondence to Barbara J. Zarowitz, PharmD, FCCP, BCPS, CGP, Omnicare, Inc., 13975 Farmington Road, Livonia, MI 48150.
    • ,
  • Richard Stefanacci, DO, CGH, MBA, AGSF, CMD

      Affiliations

    • Health Policy Institute, University of the Sciences in Philadelphia, PA
    • ,
  • Kelly Hollenack, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc., Livonia, MI.
    • ,
  • Terry O’Shea, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc., Livonia, MI.

References 

  1. Guyatt G, Rennie D. Users’ Guides to the Medical Literature: A Manual for Evidence-based Clinical Practice. Chicago, IL: AMA Press; 2002;
  2. Messinger-Rapport BJ. Evidenced-based medicine: Is it relevant to long-term care?. J Am Med Dir Assoc. 2004;5:328–332
  3. Sackett DL, Straus SE, Richardson WE, Rosenberg W, Haynes RB. Evidence-Based Medicine (How to Practice and Teach Evidence-Based Medicine). New York, NY: Churchill Livingstone; 2000;
  4. University of the Sciences in Philadelphia. Geriatric Pharmaceutical Care Guidelines. Covington, KY: Omnicare, Inc; 2005;
  5. American Society of Consultant Pharmacists Research and Education Foundation. MDS-Med Guide. Alexandria, VA: American Society of Consultant Pharmacists Research and Education Foundation; 1999;
  6. University of the Sciences in Philadelphia. Geriatric Pharmaceutical Care Guidelines. Covington, KY: Omnicare, Inc; 2006;
  7. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004;Available at: http://www.surgeongeneral.gov/library/bonehealth/content.html. Accessed July 8, 2005
  8. Office of Technology Assessment, US Congress. Hip Fracture Outcomes in People Age 50 and Over—Background Paper. OTA-BP-H-120. Washington, DC: US Government Printing Office; 1994;July
  9. Zimmerman SI, Girman CK, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int. 1999;9:151–157
  10. Office of Technology Assessment, US Congress. Effectiveness and Costs of Osteoporosis Screening ad Hormone Replacement Therapy. Volume II: Evidence on Benefits, Risk and Costs. OTA0BP-H-144. Washington, DC: US Government Printing Office; 1995;August
  11. Majumdar SR, Kim N, Colman I, et al. Incidental vertebral fractures discovered with chest radiography in the emergency department. Arch Intern Med. 2005;165:905–909
  12. Solomon DH, Morris C, Cheng H, et al. Medication use patterns for osteoporosis: An assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005;80:194–202
  13. Kanis JA, Milton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141
  14. American Geriatrics SocietyBritish Geriatrics Society and the American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. J Am Geriatr Soc. 2001;49:664–672
  15. American Association of Clinical Endocrinologists Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Prac. 2003;9:544–564
  16. Medicare Part D Drug Benefit (Access to Covered Part D Drugs (423.120)). Federal Register. 2005;70:4537–4538
  17. Watts NB, Worley K, Solis A, Doyle J, Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: Results from a managed care administrative claims database. J Manage Care Pharm. 2004;10:142–151
  18. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clinic Proc. 2002;77:453–468
  19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  21. Harris ST, Watts NB, Genant HK, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 1999;282:1344–1352
  22. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333–340
  23. Chesnut CH, Silverman S, Andriano K, et al. PROOF Study Group A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. Am J Med. 2000;109:267–276
  24. Rossouw ME, Anderson GL, Prentice RL, et al. The Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  25. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women’s Health Initiative randomized trial. JAMA. 2003;290:1729–3528
  26. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year, randomized, clinical trial. JAMA. 1999;282:637–645
  27. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  28. Karpf DB, Shapiro DR, Seeman E, et al. Alendronate Osteoporosis Treatment Study Groups Prevention of nonvertebral fractures by alendronate (A meta-analysis). JAMA. 1997;277:1159–1164
  29. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004;52:1832–1839
  30. Teriparatide (Forteo) [package insert]. Indianopolis, IN: Eli Lilly & Co; 2002.

PII: S1525-8610(06)00615-3

doi: 10.1016/j.jamda.2006.12.008

JAMDA
Volume 8, Issue 3, Supplement 2 , Pages e51-e57 , March 2007

Article Tools

* Image Usage & Resolution